Cargando…

Dapagliflozin Modulates the Fecal Microbiota in a Type 2 Diabetic Rat Model

Background: The gut microbiota is recognized as a major modulator of metabolic disorders such as type 2 diabetes. Dapagliflozin, sodium glucose cotransporter 2 inhibitors (SGLT2i), enhances renal glucose excretion, and lowers blood glucose levels. The study aimed to determine the effects of dapaglif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Mei, Shi, Fang-Hong, Liu, Wen, Zhang, Min-Chun, Feng, Ri-Lu, Qian, Cheng, Liu, Wei, Ma, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7707060/ https://www.ncbi.nlm.nih.gov/pubmed/33312157 http://dx.doi.org/10.3389/fendo.2020.00635

Ejemplares similares

Effects of Yulin Tong Bu formula on modulating gut microbiota and fecal metabolite interactions in mice with polycystic ovary syndrome
por: Su, Ya-Nan, et al.
Publicado: (2023)

Corrigendum: Effects of Yulin Tong Bu formula on modulating gut microbiota and fecal metabolite interactions in mice with polycystic ovary syndrome
por: Su, Ya-Nan, et al.
Publicado: (2023)

Dapagliflozin Attenuates Hyperglycemia Related Osteoporosis in ZDF Rats by Alleviating Hypercalciuria
por: Wang, Ji-Yu, et al.
Publicado: (2019)

Role of Dapagliflozin and Liraglutide on Diabetes-Induced Cardiomyopathy in Rats: Implication of Oxidative Stress, Inflammation, and Apoptosis
por: El-Shafey, Mohamed, et al.
Publicado: (2022)

Corrigendum: Dapagliflozin Attenuates Hyperglycemia Related Osteoporosis in ZDF Rats by Alleviating Hypercalciuria
por: Wang, Ji-Yu, et al.
Publicado: (2020)

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus
por: Saleem, Fatima
Publicado: (2017)

A Network Meta-Analysis of the Dose–Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes
por: Li, Yinhui, et al.
Publicado: (2022)

An integrated RNA sequencing and network pharmacology approach reveals the molecular mechanism of dapagliflozin in the treatment of diabetic nephropathy
por: Bai, Zhenyu, et al.
Publicado: (2022)

Effects of Sleeve Gastrectomy on Fecal Gut Microbiota and Short-Chain Fatty Acid Content in a Rat Model of Polycystic Ovary Syndrome
por: Lin, Wei, et al.
Publicado: (2021)

Correlation Between Fecal Metabolomics and Gut Microbiota in Obesity and Polycystic Ovary Syndrome
por: Zhou, Ling, et al.
Publicado: (2020)

Modulating the Microbiota as a Therapeutic Intervention for Type 2 Diabetes
por: Huda, M. Nazmul, et al.
Publicado: (2021)

Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan
por: Chen, Jung-Fu, et al.
Publicado: (2020)

Dapagliflozin Attenuates Renal Tubulointerstitial Fibrosis Associated With Type 1 Diabetes by Regulating STAT1/TGFβ1 Signaling
por: Huang, Fengjuan, et al.
Publicado: (2019)

Dapagliflozin-induced Late-onset Euglycemic Diabetic Ketoacidosis
por: Iqbal, Iqra, et al.
Publicado: (2019)

Distribution characteristics of oral microbiota and its relationship with intestinal microbiota in patients with type 2 diabetes mellitus
por: Guo, Xiao-jing, et al.
Publicado: (2023)

Frequency of Urinary Tract Infections in Type 2 Diabetic Patients Taking Dapagliflozin
por: Khan, Sarfaraz, et al.
Publicado: (2022)

Sodium glucose co-transporter 2 (SGLT2) inhibition via dapagliflozin improves diabetic kidney disease (DKD) over time associatied with increasing effect on the gut microbiota in db/db mice
por: Wu, Jiajia, et al.
Publicado: (2023)

Inulin-type fructan improves diabetic phenotype and gut microbiota profiles in rats
por: Zhang, Qian, et al.
Publicado: (2018)

A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol
por: Brown, Emily, et al.
Publicado: (2021)

Taxonomic and Functional Fecal Microbiota Signatures Associated With Insulin Resistance in Non-Diabetic Subjects With Overweight/Obesity Within the Frame of the PREDIMED-Plus Study
por: Atzeni, Alessandro, et al.
Publicado: (2022)

Sleeve gastrectomy attenuated diabetes-related cognitive decline in diabetic rats
por: Ding, Huanxin, et al.
Publicado: (2022)

Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages
por: Lin, Yi-Hsuan, et al.
Publicado: (2019)

Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis Presenting With Severe Abdominal Pain Mimicking Acute Peritonitis
por: Wang, Qianwen, et al.
Publicado: (2022)

Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report
por: Martínez-Montoro, José Ignacio, et al.
Publicado: (2022)

Puffball spores improve wound healing in a diabetic rat model
por: He, Tangtang, et al.
Publicado: (2022)

Qushi Huayu decoction ameliorates non-alcoholic fatty liver disease in rats by modulating gut microbiota and serum lipids
por: Ni, Yiming, et al.
Publicado: (2023)

Effects of Icariin on Modulating Gut Microbiota and Regulating Metabolite Alterations to Prevent Bone Loss in Ovariectomized Rat Model
por: Wang, Shanshan, et al.
Publicado: (2022)

The Role of Gut Microbiota and Environmental Factors in Type 1 Diabetes Pathogenesis
por: Dedrick, Sandra, et al.
Publicado: (2020)

Low Doses of Sucralose Alter Fecal Microbiota in High-Fat Diet-Induced Obese Rats
por: Zhang, Minchun, et al.
Publicado: (2021)

Differential effects of Akkermansia-enriched fecal microbiota transplant on energy balance in female mice on high-fat diet
por: Acharya, Kalpana D., et al.
Publicado: (2022)

Effect of Astragali radix extract on pharmacokinetic behavior of dapagliflozin in healthy and type 2 diabetic rats
por: Du, Wandi, et al.
Publicado: (2023)

Effect of Dapagliflozin on Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Single-Center Survey
por: Das, Chandan, et al.
Publicado: (2021)

Correlation Between Gut Microbiota and Testosterone in Male Patients With Type 2 Diabetes Mellitus
por: Liu, Shuang, et al.
Publicado: (2022)

Fecal microbiota transplantation alters the susceptibility of obese rats to type 2 diabetes mellitus
por: Zhang, Lijing, et al.
Publicado: (2020)

Brain Activation in Response to Low-Calorie Food Pictures: An Explorative Analysis of a Randomized Trial With Dapagliflozin and Exenatide
por: van Ruiten, Charlotte C., et al.
Publicado: (2022)

Berberine Slows the Progression of Prediabetes to Diabetes in Zucker Diabetic Fatty Rats by Enhancing Intestinal Secretion of Glucagon-Like Peptide-2 and Improving the Gut Microbiota
por: Wang, Ying, et al.
Publicado: (2021)

Expert Opinion About the Pharmacoeconomic Edge of Low-Cost Dapagliflozin in Type 2 Diabetes Mellitus in Indian Clinical Settings
por: Sharma, Kamal, et al.
Publicado: (2021)

Dapagliflozin Versus Vildagliptin as an Adjuvant to Metformin in Patients With Type 2 Diabetes Mellitus: A Randomized, Open-label Study
por: Gautam, Kumar, et al.
Publicado: (2023)

Specific alterations of gut microbiota in diabetic microvascular complications: A systematic review and meta-analysis
por: Hong, Jinni, et al.
Publicado: (2022)

Composition of the intestinal microbiota and its variations between the second and third trimesters in women with gestational diabetes mellitus and without gestational diabetes mellitus
por: Liu, Nana, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k8v00gf18tpi4c1gm06v0ieh02